Studies have suggested that the clinical use of PARP inhibitors might be extended to malignancies other than BRCA1/2-associated cancers[21,22], highlighting the need for evaluating the response of cells with different expression levels of PTEN to PARP inhibition. Here, PARP1 is linked to cancer.